Here are endorsed revisions to the WHO SAGE Roadmap for Prioritizing Uses of COVID-19 Vaccines, taking into account increasing vaccine availability, vaccine coverage rates, and the evolving epidemiological situation including variants of concern.
- Draws from comprehensive evidence reviews conducted during Q4 of 2021;
- Considers scenarios in which vaccination coverage exceeds 50% of the population;
- Includes topics such as vaccine use in children and adolescents, as well as prioritization of additional and booster doses in relation to vaccination coverage rates;
- Expands further in lower priority use groups; and
- Develops the concept of optimized vaccine use.
- Countries with low rates of primary series coverage should first achieve high primary series coverage rates among the higher priority-use groups before offering vaccine doses to lower priority-use groups;
- Countries with moderate-to-high primary series coverage in higher priority-use groups should preferentially prioritize available vaccine supply to first achieve high booster dose coverage in higher priority-use groups before offering vaccine doses to lower priority-use groups.
Updated Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine.
- Extends of the age indication down to the age of 5 years with a vaccine of reduced dosage (10 µg instead of 30 µg); and
- Recommends booster dose vaccination starting with the highest priority-use groups (e.g. older adults and health workers), 4 to 6 months after the completion of the primary series.